Case series of liver failure associated with rosiglitazone and pioglitazone

Pharmacoepidemiology and Drug Safety

Volumn 18, Issue 12, 2009, Pages 1238-1243

  Floyd, James S ^a   Barbehenn, Elizabeth ^a   Lurie, Peter ^a   Wolfe, Sidney M ^a  

^a Public Citizen   (United States)

Author keywords

Adverse event reporting; AERS; Drug induced liver injury; Hepatotoxicity; Liver failure; Pioglitazone; Rosiglitazone; Thiazolidinediones

Indexed keywords

PIOGLITAZONE; ROSIGLITAZONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DEATH; DISEASE SEVERITY; DRUG EXPOSURE; DRUG SURVEILLANCE PROGRAM; FEMALE; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER FAILURE; LIVER INJURY; LIVER TOXICITY; LIVER TRANSPLANTATION; MALE; PRESCRIPTION; PRIORITY JOURNAL; SYMPTOM; TREATMENT DURATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LIVER FAILURE; MALE; MIDDLE AGED; RISK FACTORS; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 72449202060     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1804     Document Type: Article

References (35)

1. Graham DJ, Green L, Senior JR, et al. Troglitazone-induced liver failure: a case study. Am J Med 2003; 114: 299-306. (Pubitemid 36398076)
2. U.S., Department of Health and Human Services. Rezulin to be withdrawn from the market. March 21, 2000; [U.S. Food and Drug Administration website]. Available at: http://www.fda.gov/bbs/topics/ NEWS/NEW00721.html. Accessed [December 2, 2008].
3. Product Information: Avandia [rosiglitazone]. Research Triangle Park, NC: GlaxoSmithKline; July 2008.
4. Product Information: Actos [pioglitazone]. Deerfield, IL: Takeda Pharmaceuticals America, Inc; September 2007.
5. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106-1118.
6. Singh S, Loke YK. The safety of rosiglitazone in the treatment of type 2 diabetes. Expert Opin Drug Saf 2008; 7: 579-585.
7. Forman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med 2000; 132: 118-121. (Pubitemid 30044178)
8. Al-Salman J, Arjomand H, Kemp DG, et al. Hepatocellular injury in a patient receiving rosiglitazone. A case report. Ann Intern Med 2000; 132: 121-124. (Pubitemid 30044179)
9. Ravinuthala RS, Nori U. Rosiglitazone toxicity. Ann Intern Med 2000; 133: 658.
10. Gouda HE, Khan A, Schwartz J, et al. Liver failure in a patient treated with long-term rosiglitazone therapy. Am J Med 2001; 111: 584-585. (Pubitemid 33052365)
11. Dhawan M, Agrawal R, Ravi J, et al. Rosiglitazone-induced granulomatous hepatitis. J Clin Gastroenterol 2002; 34: 582-584.
12. Bonkovsky HL, Azar R, Bird S, et al. Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone. Dig Dis Sci 2002; 7: 1632-1637. (Pubitemid 34753947)
13. Kessler W, Johnson B, Yoo H. Acute fulminant hepatic failure associated with the use of rosiglitazone. Am J Gastro 2003; 98: S212.
14. Su DH, Lai MY, Wu HP. Liver failure in a patient receiving rosiglitazone therapy. Diabet Med 2006; 23: 105-106.
15. El-Naggar MH, Helmy A, Moawad M, et al. Late-onset rosiglitazone associated acute liver failure in a patient with Hodgkin's lymphoma. Ann Pharmacother 2008; 42: 713-718. (Pubitemid 351619944)
16. Maeda K. Hepatocellular injury in a patient receiving pioglitazone. Ann Intern Med 2001; 21: 135-306.
17. Pinto AG, Cummings OW, Chalasani N. Severe but reversible cholestatic liver injury after pioglitazone therapy. Ann Intern Med. 2002; 19: 137-857.
18. Chase MP, Yarze JC. Pioglitazone-associated fulminant hepatic failure (letter). Am J Gastroenterol 2002; 97: 502-503. (Pubitemid 34160798)
19. Nagasaka S, Abe T, Kawakami A, et al. Pioglitazone-induced hepatic injury in a patient previously receiving troglitazone with success. Diabetic Med 2002; 19: 344-348. (Pubitemid 34592165)
20. May LD, Lefkowitch JH, Kram MT, et al. Mixed hepatocellularcholestatic liver injury after pioglitazone therapy. Ann Intern Med 2002; 136: 449-452. (Pubitemid 34233175)
21. Marcy TR, Britton ML, Blevins SM. Second-generation thiazolidinediones and hepatotoxicity. Ann Pharmacother 2004; 38: 1419-1423.
22. Farley-Hills E, Sivasankar R, Martin M. Fatal liver failure associated with pioglitazone. Br Med J 2004; 329: 429. (Pubitemid 39141475)
23. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006; 354: 731-739.
24. Drug Topicswebsite. http://drugtopics.modernmedicine.com/Pharmacy+ Facts+&+Figures. Accessed [April 20, 2009].
25. Weber JCP. Epidemiology of adverse reactions to nonsteroidal antiin- flammatory drugs. Adv Inflam Res 1984; 6: 1-7.
26. Rajagopalan R, Iyer S, Perez A. Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone. Diabetes Obes Metab 2005; 7: 161-169.
27. Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 2002; 25: 815-821. (Pubitemid 41094276)
28. Kaplowitz N, Lewis JH, Watkins PB. Did this drug cause my patient's hepatitis? Ann Intern Med 2003; 138: 159-160.
29. Amin P. Liver toxicity and pioglitazone: data are missing. Br Med J 2004; 329: 918. (Pubitemid 39422949)
30. Abboud G, Kaplowitz N. Drug-induced liver injury. Drug Saf 2007; 30: 277-294.
31. Pharmacology Review, Pioglitazone. http://www.fda.gov/cder/foi/nda/ 99/021073A-Actos.htm. Accessed [December 2, 2008].
32. Pharmacology Review, Rosiglitazone. http://www.fda.gov/cder/foi/ nda/99/21071-Avandia.htm. Accessed [December 2, 2008].
33. Bleibel W, Kim S, D'Silva K, et al. Drug-induced liver injury: review article. Dig Dis Sci 2007; 52: 2463-2471. (Pubitemid 47373878)
34. Graham DJ, Drinkard CR, Shatin D. Incidence of acute liver failure and hospitalized liver injury in a cohort of patients treated with troglitazone. Am J Gastroenterol 2003; 98: 175-179. (Pubitemid 36135187)
35. Scheen AJ. Hepatotoxicity with thiazolidinediones: is it a class effect? Drug Saf 2001; 24: 873-888.